ClinicalTrials.gg

Program

govorestat

Also written as “AT-007” and “Govorestat”.

Its studies are mostly in Charcot-Marie-Tooth Disease, led by Applied Therapeutics.

Furthest: phase 3, since Jul 14, 20205 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Applied Therapeutics50 open or runningphase 3since Jul 14, 2020Aug 23, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2019First study: phase 2 study in GalactosemiasFirst studyNCT04117711 · 114 enrolled · United States
  2. Jul 14, 2020Phase 3 study in GalactosemiasNCT04902781 · 47 enrolled · United States
  3. Feb 16, 2022Phase 3 study in GalactosemiasNCT05418829 · 7 enrolled · United States
  4. May 23, 2022Phase 3 study in Hereditary Neuropathy Caused by SORD DeficiencyNCT05397665 · 56 enrolled · United States, Czechia, Italy and more
  5. Sep 10, 2025Phase 3 study in Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)NCT07191912 · United States, Australia, France and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07191912Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD) · United States, Australia, France and more3WithdrawnOct 20280
NCT05397665Hereditary Neuropathy Caused by SORD Deficiency · United States, Czechia, Italy and more3CompletedOct 12, 202456
NCT05418829Galactosemias · United States3UNKNOWNNov 20227
NCT04902781Galactosemias · United States3CompletedMar 3, 202347
NCT04117711Galactosemias · United States2CompletedDec 14, 2021114

How it is read

Names in the registry

  • “AT-007”, 4 entries
  • “Govorestat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.